Fig. 8
Tbx21−/– mice are protected against primary and secondary IAV challenge. WT and Tbx21−/− B6 mice were challenged with 0.5 LD50 PR8. Shown is (a) weight loss and recovery, (b) average pathology scores from 7 dpi, and (c) viral titers at 7 dpi from groups of 3–4 mice. At 21 dpi, serum was harvested from mice infected with 0.5 LD50 PR8 and analyzed for total PR8-specific IgG. Shown is the (d) average OD reading from diluted serum from 4 mice/group (left), as well as the endpoint titers of PR8-specific IgG2a (middle) and IgG1 (left). e Naive WT mice received 50 μL of serum from PR8-primed WT or Tbx21−/– mice and were challenged with 10 LD50 PR8. Survival from 3 mice per group of serum recipients is shown vs. 5 control mice not receiving serum. Mice primed as in (a) were challenged with a A/Phil 28 days later. Shown is (f) weight loss and recovery for groups of 4 PR8-primed WT and Tbx21−/− mice vs. 3 unprimed WT mice and (g) viral titers from 8 dpi. PR8-primed mice were treated with CD8-depleting antibody prior to heterosubtypic challenge. (h) Survival is shown for groups of 4 primed mice and 3 unprimed controls. Representative of three independent experiments. BAL cells were harvested from A/Phil-challenged PR8-primed mice and CD90+CD4+ cells analyzed for surface markers (i) and cytokine production (j) (3 mice per group). In separate experiments, unprimed WT mice received 5 × 106 WT or Tbx21−/− memory OT-II cells and were challenged with PR8-OVAII. k Survival from four mice per condition is shown along with (l) analysis in separate experiments of viral titers on 4 dpi (left) and 7 dpi (right) (4 mice per group with cell transfer and 3 mice per group without cell transfer). Results representative of two similar experiments
